May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
A Study to Evaluate the Safety and Feasibility of Radiotherapy and Bevacizumab (Avastin) for the Treatment of Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration
Author Affiliations & Notes
  • E. Reichel
    Ophthalmology, Tufts-New England Eye Center, Boston, Massachusetts
  • M. Farah
    Ophthalmology, Centro Oftalmologico, Sao Paolo, Brazil
  • J. P. Duprat
    Ophthalmology, Centro Oftalmologico, Sao Paolo, Brazil
  • M. Avila
    Ophthalmology, Centro Brasileiro de Cirurgia de Oihos, Sao Paolo, Brazil
  • G. Y. Fujii
    Ophthalmology, Londrina, Londrina, Brazil
  • J. Rossi
    Ophthalmology, Londrina, Londrina, Brazil
  • A. Santos
    Ophthalmology, Puerto de Hierro Medical Center, Guadalajara, Mexico
  • B. Woodward
    NeoVista, Fremont, California
  • M. Yaqub
    NeoVista, Fremont, California
  • J. Nau
    NeoVista, Fremont, California
  • Footnotes
    Commercial Relationships E. Reichel, NeoVista, C; M. Farah, None; J.P. Duprat, None; M. Avila, None; G.Y. Fujii, None; J. Rossi, None; A. Santos, None; B. Woodward, NeoVista, E; M. Yaqub, NeoVista, E; J. Nau, NeoVista, E.
  • Footnotes
    Support None.
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 3657. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      E. Reichel, M. Farah, J. P. Duprat, M. Avila, G. Y. Fujii, J. Rossi, A. Santos, B. Woodward, M. Yaqub, J. Nau; A Study to Evaluate the Safety and Feasibility of Radiotherapy and Bevacizumab (Avastin) for the Treatment of Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2007;48(13):3657.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: To evaluate the safety and efficacy of strontium-90 delivered concomitantly with bevacizumab (Avastin) injection for the treatment of subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).

Methods:: In this prospective clinical trial, 27 patients with subfoveal CNV were treated with a radiation dose of 24 Gy using the Epi-Rad90TM Ophthalmic System and two injections of bevacizumab (1.25 mg). Patients were randomized to two cohorts. Cohort A received bevacizumab ten days (+/- 4 days) prior to surgery and one month after surgery. Cohort B received bevacizumab at the time of surgery and one month after surgery. Safety and efficacy parameters were evaluated by measuring ETDRS best-corrected visual acuity, ocular examination, fluorescein angiography, and optical coherence tomography.

Results:: To date there have been no serious adverse events (SAE) associated with the use of the Epi-Rad90TM Ophthalmic System in this population. One week after treatment, mean visual acuity improved by +6.7 ETDRS letters in the study group. Six month data on ETDRS best-corrected visual acuity, fluorescein angiography, and OCT results will be presented.

Conclusions:: Focal radiotherapy delivered concomitantly with anti-VEGF agents may provide a safe and effective alternative for patients with neovascular AMD. A large randomized prospective study is needed to fully determine the safety and efficacy of focal radiotherapy delivered concomitantly with anti-VEGF agents for the treatment of subfoveal CNV secondary to AMD.

Keywords: age-related macular degeneration • radiation therapy • choroid: neovascularization 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×